AMRX — Amneal Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $6.70bn
- $9.39bn
- $3.02bn
Brief: Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018
Brief: Amneal Announces BLA Submission Of Biosimilar Candidate To Xolair® (Omalizumab)
U.S. STOCKS ON THE MOVE-Opendoor Technologies, AIRO Group, Camurus
U.S. STOCKS ON THE MOVE-Opendoor Technologies, AIRO Group, Camurus
Amneal Pharma up after US FDA approves sodium oxybate solution
Brief: Amneal Receives U.S. FDA Approval Of Sodium Oxybate Oral Solution
Colorado must face Teva's lawsuit over free allergy pen law
Brief: Amneal Receives U.S. FDA Approval For Risperidone Extended-Release Injectable Suspension
Does a common heart attack pill help everyone? Studies disagree
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Knight Therapeutics Submits Crexont® (Carbidopa And Levodopa) Extended-Release Capsules In Mexico
Amneal Pharmaceuticals' Q2 revenue misses estimates
Amneal Pharmaceuticals Inc expected to post earnings of 18 cents a share - Earnings Preview
Brief: Amneal Pharmaceuticals Unit Prices $600 Mln Senior Secured Notes Due 2032 - SEC Filing
Brief: Knight Therapeutics Announces Filing Of New Drug Submission For Crexont® (Carbidopa And Levodopa) Extended-Release Capsules In Canada
Brief: Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R)
US FDA approves Amneal's self-administered migraine treatment (updated)
US FDA approves Amneal's migraine treatment
Amneal Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary